Cargando…

Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn’s Disease Patients through PBPK Modeling

The most common method for establishing bioequivalence (BE) is to demonstrate similarity of concentration–time profiles in the systemic circulation, as a surrogate to the site of action. However, similarity of profiles from two formulations in the systemic circulation does not imply similarity in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Chunyan, Sun, Tiancheng, Chirumamilla, Siri Kalyan, Bois, Frederic Y., Xu, Mandy, Rostami-Hodjegan, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535222/ https://www.ncbi.nlm.nih.gov/pubmed/37765205 http://dx.doi.org/10.3390/pharmaceutics15092237

Ejemplares similares

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
por: Rostami‐Hodjegan, Amin
Publicado: (2017)

Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs
por: Alrubia, Sarah, et al.
Publicado: (2022)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers
por: Wedagedera, Janak R., et al.
Publicado: (2022)

Mechanistic PBPK Modelling to Predict the Advantage of the Salt Form of a Drug When Dosed with Acid Reducing Agents
por: Chirumamilla, Siri Kalyan, et al.
Publicado: (2021)

Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling
por: Zhang, Jisheng, et al.
Publicado: (2023)

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate
por: Rostami‐Hodjegan, Amin, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018)

Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling
por: Bego, Margareta, et al.
Publicado: (2022)

In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing
por: Al-Tabakha, Moawia M., et al.
Publicado: (2020)

Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models
por: Denninger, Alexander, et al.
Publicado: (2023)

Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets
por: Usmani, Muhammad Talha, et al.
Publicado: (2023)

Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease
por: El-Khateeb, Eman, et al.
Publicado: (2023)

Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine
por: Darwich, A S, et al.
Publicado: (2013)

Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
por: Calvier, Elisa A. M., et al.
Publicado: (2018)

Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models
por: Liu, Dan, et al.
Publicado: (2020)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
por: Chetty, Manoranjenni, et al.
Publicado: (2014)

Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics.
por: Bois, F Y
Publicado: (2000)

Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics.
por: Bois, F Y
Publicado: (2000)

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations
por: Fujii, Akira, et al.
Publicado: (2009)

Esophageal Crohn's Disease Treated “Topically” with Swallowed Aerosolized Budesonide
por: Zezos, Petros, et al.
Publicado: (2010)

Hypokalemia-Induced Rhabdomyolysis From Budesonide Therapy in Crohn's Disease
por: Mansour, Ramy, et al.
Publicado: (2019)

Use of PBPK Modeling To Evaluate the Performance of DissolvIt, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products
por: Hassoun, Mireille, et al.
Publicado: (2019)

SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp(®) simulator
por: Khalidi, Hiba, et al.
Publicado: (2022)

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation
por: Duque, Marcelo Dutra, et al.
Publicado: (2019)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model
por: Shuklinova, Olha, et al.
Publicado: (2022)

Budesonide for the Induction and Maintenance of Remission in Crohn’s Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration
por: Kuenzig, M Ellen, et al.
Publicado: (2018)

Whole genome and exome sequencing of monozygotic twins discordant for Crohn’s disease
por: Petersen, Britt-Sabina, et al.
Publicado: (2014)

Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine‐Drug Interactions
por: Scotcher, Daniel, et al.
Publicado: (2020)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

Precision medicine technology hype or reality? The example of computer-guided dosing
por: Polasek, Thomas M., et al.
Publicado: (2019)

Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs
por: Daali, Youssef, et al.
Publicado: (2022)

Bioequivalence: tried and tested
por: Schall, Robert, et al.
Publicado: (2010)

Bioequivalence studies in Morocco
por: Zaoui, Sanaa, et al.
Publicado: (2020)

Bioequivalence data analysis
por: Park, Gowooni, et al.
Publicado: (2020)

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates
por: Reddy, Micaela B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1vpmh8ro5nnejs7e7lb0ckr7fk